Previous 10 | Next 10 |
With the biggest gain since at least 2016, Merck (MRK +8.8%) hit a 52-week high in reaction to promising early data posted with its partner Ridgeback Biotherapeutics, for the oral COVID-19 therapy, molnupiravir. In an interim analysis of a late-stage trial involving patients with mild-to-mode...
Shares of the mid-cap biopharma Atea Pharmaceutical (NASDAQ: AVIR) are up by a respectable 21.5% as of 11:44 a.m. EDT Friday morning. The biotech's shares are taking flight today in response to a successful interim analysis for Merck 's oral COVID-19 pill, molnupiravir, in a...
Gainers: Progenity (NASDAQ:PROG) +29%, Biomerica (NASDAQ:BMRA) +28%, Atea Pharmaceuticals (NASDAQ:AVIR) +19%, Silverback Therapeutics (NASDAQ:SBTX) +13%, Codexis (NASDAQ:CDXS) +12%. Losers: Omeros (NASDAQ:OMER) -41%, Adagio Therapeut...
Biomerica (NASDAQ:BMRA) +38% Walmart now selling Biomerica’s EZ Detect™ colorectal screening test Atea Pharmaceuticals (NASDAQ:AVIR) +29%. TDH Holdings (NASDAQ:PETZ) +17%. Progenity (NASDAQ:PROG) +25%. Bitfarms (NASDAQ:BITF) +14% amid equity weakness, El Salvador minin...
Gainers: Alzamend Neuro (NASDAQ:ALZN) +52%, Progenity (NASDAQ:PROG) +18%, OptimizeRx (NASDAQ:OPRX) +15%, Atea Pharmaceuticals (NASDAQ:AVIR) +14%, Perrigo (NYSE:PRGO) +11%. Losers: Corvus Pharmaceuticals (NASDAQ:CRVS) -15%, NuCana (NASDAQ:NCNA)...
BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea mana...
A sell-off that began in China spread to other global financial markets on Monday. Along with a sharp slide in U.S. equities, the cryptocurrency market suffered a major decline. Given the crypto sell-off, stocks tied to that asset class experienced an outsized decline during the session. This...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +98%. Edesa (NASDAQ:EDSA) +68%. Sentage (NASDAQ:SNTG) +21%. Viveve (NASDAQ:VIVE) +19%. Aterian (NASDAQ:ATER) +15%. Atea Pharmaceuticals (NASDAQ:AVIR) +12%. Corvus (NASDAQ:CRVS) +13%. Five Star (NASDAQ:FVE) +12%. BEST (NYSE:BEST) +10%. Petros Pharmaceutic...
Shares of biotech company Atea Pharmaceuticals (NASDAQ: AVIR) are up 16.8% as of mid-Monday, although not in response to news from or about the company. Rather, a U.S. Food and Drug Administration advisory panel's recent recommendation against COVID-19 vaccine boosters (for most peo...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +155%, Edesa Biotech (NASDAQ:EDSA) +34%, Atea Pharmaceuticals (NASDAQ:AVIR) +20%, Synlogic (NASDAQ:SYBX) +13%, Viveve Medical (NASDAQ:VIVE) +9%. Losers: BeyondSpring (NASDAQ:BYSI) -22%, Protagonist Therap...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...